Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)

AxoGen (AXGN) is described as technically oversold after heavy selling, while Wall Street analysts are said to be revising earnings estimates higher. The article suggests these factors could support a trend reversal but gives no estimate figures or evidence that a reversal has begun.